Put companies on watchlist
STRATEC SE
ISIN: DE000STRA555
WKN: STRA55
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

STRATEC SE · ISIN: DE000STRA555 · EQS - Company News (53 News)
Country: Germany · Primary market: Germany · EQS NID: 1514439
15 December 2022 03:34PM

STRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE


EQS-News: STRATEC SE / Key word(s): Conference
STRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

15.12.2022 / 15:34 CET/CEST
The issuer is solely responsible for the content of this announcement.


STRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Birkenfeld, December 15, 2022

STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at the Westin St. Francis in San Francisco, CA, USA. Marcus Wolfinger, Chief Executive Officer of STRATEC SE, will represent the company in a session scheduled at 11:15 am PST (2:15 pm EST / 7:15 pm GMT / 8:15 pm CET).

The presentation will be webcast live and can be accessed on the company’s website at www.stratec.com in the Investors section under Events & Presentations. A replay of the webcast will be available after the presentation and will remain available for 30 days.

ABOUT STRATEC
STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For its analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler | Investor Relations, Sustainability & Corporate Communications
Tel: +49 7082 7916-6515
ir@stratec.com
www.stratec.com



15.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec.com
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1514439

 
End of News EQS News Service

1514439  15.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1514439&application_name=news&site_id=boersengefluester_html
Visual performance / price development - STRATEC SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.